Characterization of human immunodeficiency virus drug-resistance mutations among individuals with low-level-viremia in low-income and middle-income countries: A meta-analysis

Table 2 Prevalence of drug resistance mutations: Subgroup analysis, % (95%CI)

Outcome	Continent			Number of sites
	Africa	Asia	P value	Single	Multiple	P value
Overall	58.0 (30.8-85.2)	40.7 (26.0-55.5)	< 0.0001	52.8 (39.3-66.3)	41.7 (11.0-72.3)	< 0.0001
Nucleoside reverse transcriptase inhibitor mutation	57.9 (53.9-61.9)	34.7 (33.3-36.1)	< 0.0001	47.3 (42.2-52.4)	16.7 (7.4-30.4)	< 0.0001
Non-nucleoside reverse transcriptase inhibitor mutation	61.6 (44.5-78.8)	36.2 (26.4-46.1)	< 0.0001	48.7 (39.3-58.1)	78.9 (63.7-88.9)	< 0.0001
Protease inhibitors mutation	7.3 (3.4-11.2)	4.1 (3.4-4.9)	< 0.0001	4.9 (3.5-6.3)	15.8 (7.4-30.4)	< 0.0001